ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent
A legfontosabb adatok
- Ki végzi
- Edwards Lifesciences
- Hol
- Atlanta, Aurora, Charlottesville, Cincinnati, Columbus, Dallas, Houston, Los Angeles, New York, Philadelphia, San Francisco, Seattle és St Louis (Egyesült Államok)Mind a 14 helyszín megnézése
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 86 fő vett részt
- Kezdés
- 2017. aug. 22.
- Várható befejezés
- 2032. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
- A regiszteradat frissítve
- 2026. október 20.
Ki vehet részt
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- The candidate/candidate's legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent
- Weight is ≥ 20 kg (44 lbs)
- RVOT/PV with moderate or greater PR by TTE
- RVOT/PV proximal and distal landing zone diameter ≥ 27 mm and ≤ 38 mm, and minimum of 35 mm from contractile tissue to lowest pulmonary artery takeoff
Ki nem vehet részt
- History of or active endocarditis (active treatment with antibiotics) within the past 180 days
- Need for concomitant atrial septal defect or ventricular septal defect closure or other concomitant interventional procedures other than pulmonary artery or branch pulmonary artery stenting or angioplasty
- Interventional/surgical procedures within 30 days prior to the Alterra or valve implant procedure
- Any planned surgical, percutaneous coronary or peripheral procedure to be performed within the 30 day follow-up from the Alterra or valve implant procedure
- Known hypersensitivity to aspirin or heparin and cannot be treated with other antiplatelet and/or antithrombotic medications
- Currently participating in an investigational drug or another device study [Note: Trials requiring extended follow up for products that were investigational, but have since become commercially available, are not considered investigational devices.]
- Active infection requiring current antibiotic therapy (if temporary illness, patient may be a candidate 2 weeks after discontinuation of antibiotics)
- History of or current intravenous drug use
- Major or progressive non-cardiac disease resulting in a life expectancy of less than one year
- Known hypersensitivity to nitinol, cobalt-chromium, nickel or contrast media that cannot be adequately pre-medicated
- Leukopenia (WBC < 2000 cells/μL), anemia (Hgb < 7 g/dL), thrombocytopenia (platelets < 50,000 cells/μL) or any known blood clotting disorder
- Positive urine or serum pregnancy test in female patients of child-bearing potential
- Renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy
- Inappropriate anatomy for introduction and delivery of the Alterra Adaptive Prestent or the SAPIEN 3 THV
Helyszínek itt: Egyesült Államok
- Emory University & Children's Healthcare of Atlanta (CHOA)Atlanta, Egyesült Államok
- Children's Hospital ColoradoAurora, Egyesült Államok
- University of VirginaCharlottesville, Egyesült Államok
- Cincinnati Children's HospitalCincinnati, Egyesült Államok
- Nationwide Children's HospitalColumbus, Egyesült Államok
- Children's Health DallasDallas, Egyesült Államok
- Texas Children's HospitalHouston, Egyesült Államok
- Cedars-Sinai Medical CenterLos Angeles, Egyesült Államok
- University of California, Los AngelesLos Angeles, Egyesült Államok
- Columbia University Medical CenterNew York, Egyesült Államok
- Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
- University of California San FranciscoSan Francisco, Egyesült Államok
- Seattle Children's HospitalSeattle, Egyesült Államok
- St. Louis Children's HospitalSt Louis, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated for treatment of pulmonary regurgitation (PR).
A teljes eredeti leírásKevesebb
Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
A vizsgálat 2 csoportja
- TPVR - Main CohortA vizsgált kezelés
Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Commander Delivery System.
Kezelés: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
- TPVR - PDS RegistryA vizsgált kezelés
Implantation of Edwards Alterra Adaptive Prestent and Edwards SAPIEN 3 THV using Pulmonic Delivery System (PDS).
Kezelés: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Multicenter Study of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 THV With the Alterra Adaptive Prestent
- A regiszteradat frissítve
- 2026. október 20.